Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × ACE-011 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 4 Multiple Myeloma 3 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Primary Myelofibrosis 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 135 Gemcitabine 122 Capecitabine 114 Fluorouracil 106 Paclitaxel 105 Oxaliplatin 96 Bevacizumab 95 Nivolumab 92 Leucovorin 89 Docetaxel 84 Radiosurgery 83 Irinotecan 78 Cisplatin 75 Carboplatin 75 Magnetic Resonance Spectroscopy 65 Cyclophosphamide 62 Cetuximab 62 Specimen Handling 56 Biopsy 56 Radiotherapy 52 Trastuzumab 51 Ipilimumab 45 Drug Therapy 45 Everolimus 41 Albumin-Bound Paclitaxel 40 Pemetrexed 39 130-nm albumin-bound paclitaxel 39 Fulvestrant 36 Doxorubicin 36 aldesleukin 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00931606 2023-09-13

MK-7962-012

Merck Sharp & Dohme LLC

Phase 2 Terminated

30 enrolled 32 charts

Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡